Search

LEIDEN, the Netherlands, Oct. 02, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept.

Le QR-110 a permis une amélioration rapide et soutenue de la vision chez la majorité des sujets, tant en termes d’acuité visuelle que de mobilité Le QR-110 a été bien toléré sans événements indésirables graves

QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course QR-110 was well-tolerated with no serious adverse events

Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th

LEIDEN, The Netherlands, Aug. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

LEIDEN, the Netherlands, Aug. 01, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.